DTech Liquidating

DTech Liquidating Revenue per Employee

Delisted

The Revenue per Employee of DTech Liquidating (DMTKQ) as of Nov 18, 2026 is 55,021.58 USD. In the previous year, Revenue per Employee was 52,230.22 USD — a change of 5.34% (higher).

Revenue per Employee

55,021.58USD

YoY

5.34%

Last updated:

Revenue per Employee of DTech Liquidating is 2023 55,021.58 USD. Revenue per Employee of DTech Liquidating was 2022 52,230.22 USD. It decreases by 5.34% higher compared to the previous year.

The DTech Liquidating Revenue per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Employee
Date
Revenue per Employee
Jan 1, 2019
12,086.33 USD
Jan 1, 2020
21,187.05 USD
Jan 1, 2021
42,589.93 USD
Jan 1, 2022
52,230.22 USD
Jan 1, 2023
55,021.58 USD
The DTech Liquidating Revenue per Employee history
YEARRevenue per EmployeeYoY
55,021.58USD+5.34%
52,230.22USD+22.64%
42,589.93USD+101.02%
21,187.05USD+75.30%
12,086.33USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

Revenue per Employee of DTech Liquidating is 55,021.58 USD in 2023.

Revenue per Employee of DTech Liquidating changed from 52,230.22 USD to 55,021.58 USD, representing a 5.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Employee DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

Revenue per employee measures workforce productivity by dividing total revenue by the number of employees. Higher values indicate more efficient operations.

Revenue per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Revenue per Employee's DTech Liquidating historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — DTech Liquidating

All Key Metrics — DTech Liquidating